Dec 31, 2013 by Eric HoInsurance Ups and Downs for Diabetes Drugs in 2014Managed care titans CVS Caremark and Express Scripts are undertaking major changes to their preferred drug formularies that may significantly impact a number of well-known diabetes medications and manufacturers.
Dec 31, 2013 by Eric HoZogenix, Zohydro ER Face Familiar Post-Approval HurdlesIn a familiar echo for pain medications in the past, state attorneys across the US have submitted new concerns over Zogenix and Zohydro ER that may seriously dampen its success or influence the FDA to recall Zohydro's approval entirely...
Dec 30, 2013 by Eric HoPayor Trouble for Advair, GlaxoSmithKline Drugs in 2014A number of well-known GlaxoSmithKline drugs, including one major blockbuster, will no longer be covered by the largest pharmacy benefit manager in the U.S. beginning Jan. 1.
Dec 23, 2013 by Eric HoRite Aid, Walgreen, and CVS: Can In-Store Care Push Pharmacy Stocks Forward?The tide has turned dramatically for in-store care clinics at major pharmacy retailers over the last few years. While previously growth for these services had stalled due to lack of dialogue between providers, new waves of partnerships for CVS, Walgreen, and Rite Aid are changing the game for convenient care.
Dec 12, 2013 by Eric HoThe Weight Loss Drug Company Investors Need to Watch Out ForBig names like GlaxoSmithKline, Arena, VIVUS, and Orexigen are probably well-known among obesity market watchers, but this less publicized company out of Massachusetts is poised to change the landscape in coming years.
Dec 2, 2013 by Eric HoCVS Caremark's Big Thanksgiving Purchase: The Coram BuyoutThe oft-overlooked home infusion and alternative site infusion market represents a huge opportunity for CVS Caremark with its recent acquisition of leading infusion provider Coram Specialty Infusion Services.
Nov 26, 2013 by Eric HoThe Good News, Bad News for Belviq: …Now the Good NewsWhile Arena Pharmaceuticals' Belviq may need time to gain traction, it may have many of the right pieces in the right places to realize its long-term prospects
Nov 21, 2013 by Eric HoThe Good News, Bad News for Belviq: Bad News First…Arena Pharmaceuticals' Belviq continues to stall despite huge early expectations. Let's take a look at the current barriers and potential future success for Belviq...
Nov 15, 2013 by Eric HoEteplirsen in Question: Hope for SareptaRecent decisions by the Food and Drug Administration poses new questions about Sarepta Therapeutics, eteplirsen, and the future of DMD treatment.
Nov 6, 2013 by Eric HoPain and Abuse: The Challenge in Bringing Zohydro to MarketRecent developments in controlled substance rules may help Zogenix's extended-release hydrocodone product to market when it will need all the help it can get.
Nov 4, 2013 by Eric HoWalgreen and the Biggest Biotech Startup You've Never Heard OfWalgreen's new partnership could change the way we think of pharmacies.
Oct 21, 2013 by Eric HoThe Clinical Lowdown: Keryx and ZerenexA second opinion on the recent Keryx rush.
Oct 14, 2013 by Eric HoMannKind Bulls Should Prepare for the Long HaulAfrezza could be a blockbuster, but will physicians wait and see?